CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization

By sjmartinez • October 5, 2023

Luebker S, Frech TM, Assassi S, Skaug B, Gordon JK, Lakin K, Bernstein EJ, Luo Y, Steen VD, Shah AA, Hummers LK, Richardson C, Moore DF, Khanna D, Castelino FV, Chung L, Kapoor P, Hant FN, Shanmugam VK, VanBuren JM, Alvey J, Harding M, Shah A, Makol A, Lebiedz-Odrobina D, Thomas JK, Volkmann ER, Molitor JA, Sandorfi N. CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization. Rheumatology (Oxford). 2023 Oct 3;62(10):3433-3438. doi: 10.1093/rheumatology/kead176. PMID: 37079727; PMCID: PMC10547507.

Tags: gastrointestinal tract, health outcomes, health status, Publications, Rheumatology, SSc

Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review

Leiva O, Liu O, Kanelidis A, Swat S, Gozdecki L, Belkin M, Grinstein J, Kalantari S, Kim G, DeCara J, Chung B, Patel A, Odenike[...]

Self-Reported Resilience During the COVID-19 Pandemic

Ogungbe O, Wang T, Balte PP, Slone SE, Meyer D, Allen NB, Buhr RG, Hirsch JA, Hinckley Stukovsky K, Kucharska-Newton A, Gabriel KP, Regan EA,[...]

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma

Armand P, Zinzani PL, Timmerman JM, Johnson NA, Lavie D, Thiagarajan K, Topp B, Pillai PM, Herrera AF. Estimating efficacy of favezelimab plus pembrolizumab relative[...]